Overview

OTT166 in Diabetic Retinopathy (DR)

Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
Phase:
Phase 2
Details
Lead Sponsor:
OcuTerra Therapeutics, Inc.
Collaborator:
Parexel